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Induced Cardiovascular Procedural Costs
and Resource Consumption Patterns After
Coronary Artery Calcium Screening
Results From the EISNER (Early Identification of
Subclinical Atherosclerosis by Noninvasive Imaging Research) Study
Leslee J. Shaw, PHD,* James K. Min, MD,† Matthew Budoff, MD,‡ Heidi Gransar, MS,§
Alan Rozanski, MD, Sean W. Hayes, MD,§ John D. Friedman, MD,§
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Objectives We prospectively evaluated procedural costs and resource consumption patterns in the EISNER (Early Identification of
Subclinical Atherosclerosis by Noninvasive Imaging Research) study after coronary calcium (CAC) measurements.
Background Controversy surrounds expansion of cardiovascular disease (CVD) screening to include atherosclerosis imaging
as the result of concern whether induced costs will outweigh any benefit.
Methods Detailed risk factor and CAC measurements with 4-year follow-up for CVD death or myocardial infarction and proce-
dures were performed. Costs were estimated with the use of Medicare reimbursement rates (discounted and inflation
corrected). Cox survival analysis was used to estimate procedures and events.
Results CAC scores varied widely but were skewed toward low scores with 56.7% of screened subjects having CAC
scores 10 and only 8.2% having CAC scores 400. Noninvasive testing was infrequent and medical costs were
low among subjects with low CAC scores, both rising progressively with increasing CAC scores (p  0.001), par-
ticularly in the 31 (2.2% of subjects) that had CAC scores 1,000. Similarly, invasive coronary angiography rose
progressively with increasing scores (p  0.001) but occurred exclusively among subjects first undergoing nonin-
vasive testing and overall, was performed in only 19.4% of subjects with CAC scores 1,000.
Conclusions CAC scanning is associated with a marked differential in downstream frequency of medical tests and costs,
ranging from a very low frequency of testing and invasive procedures among a predominantly large percentage
of subjects with low CAC scores, to selectively concentrated testing and procedures among a small number of
subjects with CAC scores 400. Thus, CAC scanning appears to foster efficient selective testing patterns among
asymptomatic individuals at risk for CVD. (J Am Coll Cardiol 2009;54:1258–67) © 2009 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.018h
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ccepted July 6, 2009.ealth care coverage decisions. Recent technology evalua-
ions and statements by the U.S. Preventive Services Task
orce have voiced strong concerns over the untoward
onsequences of CVD screening, including the potential for
nwarranted, induced testing after a diagnosis of subclinical
therosclerosis (1). Past arguments (2–4) have cautioned
See page 1268
gainst embarking on nationwide screening for CVD
ecause of a lack of high-quality evidence on the subject.
uring the past few years, a number of large observa-
ional, prospective registries (2–4) have reported on the
rognostic accuracy of CVD screening to detect coronary
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September 29, 2009:1258–67 Costs of Coronary Calcium Screeningrtery calcification (CAC). This modality has been shown
o effectively risk stratify women and men of diverse
thnicity (2–4).
However, the concern remains that testing will beget
ore testing and that the initiation of a strategy for the
etection of subclinical atherosclerosis may result in early
nd lifelong greater patterns of resource consumption that
ould not have been realized without the initial documen-
ation of measureable CVD (1,5). The EISNER (Early
dentification of Subclinical Atherosclerosis by Noninvasive
maging Research) study initiated a prospective registry of
ndividuals with documented cardiac risk factors who agreed
o be enrolled and undergo clinical risk assessment and
ubclinical atherosclerosis screening with computed tomo-
raphic measurement of CAC. The EISNER study is
omposed of several substudies. We will report on individ-
als enrolled in the EISNER I study who were followed for
years for the end point of CVD resource consumption and
rocedural costs as well as clinical outcomes.
ethods
f the 1,381 participants enrolled in this EISNER sub-
tudy, a total of 1,361 (98.6%) were available for this
nalysis. All enrollees were volunteers who were recruited
rom study advertisement across the medical center and to
he general public under the supervision and approval of our
nstitutional review board from May 2001 to June 2005.
nrolled subjects were not paid for participation, nor were
hey asked to pay for any study testing. Qualified enrollees
ad no cardiac symptoms or previous history of CVD. Study
oordinators preferentially recruited those with 1 or more
ardiac risk factors. Exclusion criteria included age 80
ears, pregnancy, significant comorbidity, previous CAC
canning, and inability to complete 4 years of follow-up. All
ubjects provided written informed consent and agreed to
articipate in the follow-up portion of this study. Results
rom other EISNER substudies have been previously pub-
ished (6–8).
aseline clinical risk factor screening. At the time of the
aseline visit, each enrollee had arterial blood pressure and
asting measurements of lipids and glucose. The fasting
ipid profile (total cholesterol, high-density lipoprotein cho-
esterol, and triglycerides, with calculated low-density li-
oprotein cholesterol) and serum glucose level was per-
ormed on each study participant by a Cholestech
Hayward, California) desktop chemical analyzer. Height,
eight, hip, and waist measurements also were ascertained
rom each enrollee. Body mass index was calculated by
ividing weight by height measurements (kg/m2). Patients
lso completed a questionnaire on risk factors and medica-
ion use during the index visit.
From the measured risk factor data, the Framingham
isk Score (FRS) was calculated to estimate a patient’s
0-year risk of CVD death or myocardial infarction (MI)
9,10). A low-risk FRS was 10%, intermediate risk was c0% to 20%, and high risk was
20%. Patients with diabetes
ere categorized with a high
RS.
AC scanning. Scanning was
erformed by the use of electron
eam tomography (Imatron
-150, Imatron, a division of GE,
ilwaukee, Wisconsin), GE
-Speed (GE Healthcare), or Sie-
ens Volume Zoom (multislice
omputed tomography, Siemens
edical Systems, Munich, Ger-
any). Imaging protocols were
onsistent with accepted standards
6,8,11). Each scan involved ac-
uisition of 30 to 40 slices of 3.0
r 2.5 mm for electron beam
omography and multislice com-
uted tomography with triggering at 50% to 80% of the
ardiac cycle. Instructions for breathholding were given to
atients to minimize misregistration. The foci of CAC were
erformed by experienced technologies that scored each
can by the use of semiautomatic commercial software
NetraMD, ScImage, Los Altos, California). The CAC was
cored after detection of a minimum of 3 contiguous pixels
voxel size 1.03 mm3) with peak density 130 Hounsfield
nits (HU) within a given coronary artery segment. All
coring was reviewed by an experienced cardiologist. The
AC score was calculated by the product of the area of each
alcified focus and peak HU (score  1, 131 to 199 HU;
core 2, 200 to 299 HU; score 3, 300 to 399 HU; score
4,400 HU) (12). A summed CAC score was calculated
rom all segmental lesions in the left main, left anterior
escending, right coronary, and left circumflex arteries.
ollow-up resource consumption. All enrollees were fol-
owed yearly through a mailed questionnaire; culminating in
4-year clinic visit. Yearly questionnaires documented cardiac
isk factor status, ongoing medical therapies, and intercurrent
VD procedures or hospitalizations. Follow-up CVD proce-
ures analyzed were exercise treadmill resting, stress myocar-
ial perfusion imaging, stress echocardiography, coronary com-
uted tomographic angiography (CCTA), and invasive
oronary angiography (ICA). The timing and occurrence of
ercutaneous coronary intervention or coronary bypass surgery
as documented. Invasive procedures were confirmed by
ource documentation or through confirmation with the sub-
ect’s primary care physician.
linical outcome measurement. During the course of
ollow-up, the occurrence of CVD death or nonfatal MI
as ascertained. We defined CVD death as fatal MI or
troke and death related to heart failure or peripheral arterial
isease. The diagnosis of nonfatal MI included admission
ith a primary or secondary diagnosis confirmed by enzy-
atic elevation and electrocardiographic (ECG) changes
Abbreviations
and Acronyms
CAC  coronary artery
calcium/calcification
CCTA  coronary
computed tomographic
angiography
CVD  cardiovascular
disease
ECG 
electrocardiographic/
electrocardiogram
FRS  Framingham Risk
Score
HU  Hounsfield units
ICA  invasive coronary
angiography
MI  myocardial infarctiononsistent with acute infarction. The timing and occurrence
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Costs of Coronary Calcium Screening September 29, 2009:1258–67f CVD death or MI was collected during each year of
ollow-up. Death status was confirmed by medical record
eview, through the Social Security Death Index, or from
os Angeles County Public Health records. Hospitalization
or acute MI was confirmed by the subject’s primary care
hysician and/or medical record review. A total of 1.4% of
atients was lost to follow-up. At years 1, 2, 3, and 4,
ollow-up rates were 99%, 96%, 95%, and 99%, respectively.
ost measurements. Nationwide, average Medicare
iagnosis-related group reimbursement rates were applied
o define hospital costs using the PC Pricer Prospective
ayment System estimator (13). Costs for outpatient ser-
ices were derived by use of the Outpatient Prospective
ayment amounts (nationwide and specific locality) based
n Healthcare Common Procedure Codes. Drug costs were
erived from the Medicare planner for retail and mail-order
harmacy charges. Costs were inflation-adjusted by use of
he medical care component of the consumer price index
nd discounted 3% per year to reflect the lower economic
alue of deferred expenses. Our cost analyses used the
ocietal perspective as recommended by the National Panel
n Cost-Effectiveness in Health and Medicine (14).
tatistical analyses. Comparisons of CAC subsets by con-
inuous measures, such as low-density lipoprotein choles-
erol, were calculated by the nonparametric Wilcoxon sta-
istic. Median and 25th to 75th percentile measures were
alculated. Categorical variables, such as cardiac risk factors,
ere compared by linear-by-linear association chi-square
tatistics. Time-to-CVD procedures were estimated by
aplan-Meier survival curves by the use of a Wilcoxon rank
um test. Rates for years 1, 2, and 4 were calculated. A
ogistic regression model was used to estimate aspirin,
tatin, and ICA use. From the model, estimated probabil-
ties of ICA were calculated. The probabilities of ICA were
lotted by the CAC score. An odds ratio (95% confidence
nterval) was calculated for CAC subsets of 11 to 100, 101
o 399, 400 to 999, and 1,000. For revascularization,
90-day, 1-year, and 4-year rates were calculated.
otal procedural costs were summed and compared across
AC subsets by the nonparametric Wilcoxon statistic. A
inear regression model also was used to estimate predictors
f cost. Finally, Kaplan-Meier survival curves were plotted
o estimate time to death or MI for the CAC and FRS
ubsets. Additionally, a Cox proportional hazards model
as used to calculate hazard ratios and 95% confidence
ntervals.
esults
ardiac risk factors and FRS subsets. Individuals with
ore extensive CAC scores were more likely to be older,
ale, and with prevalent risk factors (Table 1). Many of the
urrent enrollees were receiving risk factor modifying ther-
pies with their FRS calculated on-therapy. The median
RS was 6 (25th, 75th percentile: 2, 12), with 40% being at
ntermediate risk. nollow-up new statin and aspirin use. Similar to other
eports, the FRS-adjusted odds of new statin use at 4 years
as elevated 2.57-fold (25th, 75th percentile: 1.72, 3.83,
 0.0001), 2.89-fold (25th, 75th percentile: 1.78, 4.69, p 
.0001), 4.81-fold (25th, 75th percentile: 2.50, 9.28, p 
.0001), and 14.22-fold (25th, 75th percentile: 5.15, 39.29,
 0.0001) for those with CAC scores of 0 to 10, 11 to
00, 101 to 399, 400 to 999, and 1,000, respectively.
imilarly, the FRS-adjusted odds of new aspirin consump-
ion was increased 2.75- to 4.62-fold for the same CAC
ubsets (p  0.0001).
ollow-up noninvasive procedural utilization. During
ollow-up, noninvasive procedures were frequently per-
ormed (Fig. 1, Tables 2 and 3). Follow-up ECGs and
readmill tests were performed in 57% and 27% of subjects.
ne-half of subjects with a CAC score 11 had a routine
CG performed during follow-up as compared with 62% to
0.2% of those with scores 11 to 399 to 1,000 (p 
.0001). A nonimaging exercise ECG was performed in
9.5% to 61.3% of those with a CAC score from 0 to 10 to
1,000 (p  0.0001).
Cardiac imaging, including stress echocardiography or
yocardial perfusion single-photon emission computed to-
ography, was performed in 15.2% and 11.7% of enrollees.
igure 1A plots the cumulative rates of stress cardiac
maging after index CAC scanning (p  0.0001). By 1 year
f follow-up, few individuals with a low CAC score of 0 to
0 had a follow-up stress imaging procedure. Rates of stress
maging increased over time and more commonly were
erformed in those with a CAC score of400. By year 1 of
ollow-up, 36.9% and 44.5% of individuals with a CAC
core of 400 to 999 and 1,000 had stress imaging study
erformed. The highest 4-year rate of stress imaging was in
hose with a CAC of 1,000 with 86.8% of the 31
ndividuals undergoing this procedure.
A total of 7.9% of subjects had a follow-up CCTA.
igure 1B plots the cumulative rate of CCTA after index
AC scanning (p  0.0001). Rates of CCTA were lowest
or patients with less-extensive CAC scores and highest for
atients with extensive CAC. Of the 773 individuals with a
AC score from 0 to 10, only 2.3% underwent CCTA.
A further analysis of the frequency of procedures revealed
hat for patients with CAC scores of 0 to 10, 90% did not
ave any procedures through 1 year of follow-up (Table 2).
onversely, follow-up testing (including multiple proce-
ures) was common for those with a CAC score 400.
Noninvasive test layering that included a combination of
AC followed by exercise treadmill testing with a stress
maging test occurred in 11.3% to 51.6% of those with CAC
cores 10 to 1,000 (p  0.0001) (Table 3). Noninvasive
rocedural use did not vary by the FRS (p  0.718) in an
djusted model containing CAC (p  0.0001). For those
ith a CAC score 10, current smoking (p  0.019) and
ge 60 years (p  0.004) were associated with more
oninvasive follow-up testing (p  0.019).
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September 29, 2009:1258–67 Costs of Coronary Calcium Screeningollow-up invasive procedural use. A total of 92 ICAs
ere reported during follow-up. Similar patterns of greater
se in individuals with greater CAC scores was noted for
CA (Table 3). The rates of ICA were low at 1 year of
ollow-up and ranged from 0.3% to 3.5% for those with
AC scores from 1,000 (p  0.0001) (Fig. 2A) and
emained low (i.e., 10%) for most of follow-up. By year 6,
ollow-up ICA use was greater for patients with a CAC
core from 400 to 999 (13.5%) and 1,000 (36.7%). The
robability of ICA was 1% for those with a CAC score
rom 0 to 10 but increased in a directly proportional manner
ith more extensive CAC score (Fig. 2B).
A total of 13 coronary artery bypass surgeries and 44
ercutaneous coronary interventions were reported dur-
ng follow-up. The resulting early revascularization
ates were low, with only 3 individuals undergoing
oronary revascularization within 90 days of follow-up
Table 4). The majority (31 of 157) of the revasculariza-
ion procedures occurred in those with CAC scores 400
p  0.0001).
Importantly, invasive testing occurred exclusively in pa-
ients with a previous noninvasive procedure. Test layering
aseline Clinical Risk Factor Characteristics of the EISNER CohortTable 1 Baseline Clinical Risk Factor Characteristics of the EIS
Coronar
0–10
(n  773)
11–100
(n  287)
Age (yrs) 56 (50, 61) 60 (55, 65)
Women 45.1 38.7
BMI 26 (24, 29) 27 (24, 30)
Lipids
Total cholesterol 213 (189, 239) 210 (185, 244)
LDL cholesterol 132 (110, 157) 132 (107, 160)
HDL cholesterol 53 (43 ,66) 50 (40, 60)
TG 106 (78, 156) 119 (82, 175)
Glucose 92 (85, 99) 94 (86, 103)
Blood pressure
Systolic 128 (119, 140) 133 (123, 146)
Diastolic 81 (75, 88) 82 (78, 90)
Risk factors
Hypertension 51.6 63.1
Hyperlipidemia 64.0 72.8
Diabetes 5.6 11.8
Family history of
premature CHD
27.2 28.6
Smoking 7.1 7.3
FRS 5 (2, 10) 10 (4, 17)
Low 72.4 46.0
Intermediate 25.6 36.9
High 2.0 17.1
Medications
Statins 19.3 26.3
Aspirin 10.2 10.7
alues are median (25th, 75th percentile) or %. All cholesterol and glucose values are presented in
resented in mm Hg.
CHD  coronary heart disease; EISNER  Early Identification of Subclinical Atherosclerosis b
riglycerides.here invasive testing followed noninvasive testing occurred cn 0.8% to 19.4% of those with a CAC score10 to1,000
p  0.0001) (Table 3).
nnual procedural and overall costs. Both procedural and
verall costs increased progressively with increasing CAC
cores (p  0.0001 for both). Mean costs were lowest for
hose with a CAC score 10 (Table 5). Costs expended on
rocedures increased sharply for the 31 subjects with CAC
cores 1,000 as did overall medical costs. However, since
his subgroup constituted just 2.2% of the total study cohort,
ts medical expenditure accounted for only 12.9% of the
otal medical costs within the study cohort. Procedural and
rug costs encumbered 28.9% (25th, 75th percentile: 8.1%,
00%) and 60.4% (25th, 75th percentile: 0.0%, 91.1%) of
verall 4-year costs.
Intermediate- and high-risk FRS individuals had greater
osts than those with a low FRS. By using a linear
egression model estimating procedural cost, we found that
ach increase in FRS risk group was associated with an
ncrease in 4-year cost of $224.39 and each increase in the
AC subsets was associated with an increase in 4-year cost
f $493.60. In this model, the presence of diabetes was not
ssociated with greater procedural costs (p 0.35). Procedural
Cohort
ry Calcium Score
p Value
–399
187)
400–999
(n  83)
>1,000
(n  31)
7, 67) 63 (59, 69) 66 (60, 70) 0.0001
2.2 25.3 19.4 0.0001
4, 31) 27 (25, 31) 27 (24, 32) 0.172
87, 238) 207 (185, 236) 204 (175, 257) 0.73
08, 157) 136 (110, 156) 119 (99, 149) 0.94
1, 64) 48 (40, 59) 51 (40, 56) 0.006
7, 172) 118 (83, 158) 128 (86, 165) 0.046
7, 104) 96 (88, 108) 97 (88, 106) 0.0001
22, 149) 137 (125, 150) 146 (131, 157) 0.0001
7, 90) 82 (80, 90) 84 (78, 92) 0.0001
4.2 75.9 77.4 0.0001
9.0 80.7 67.7 0.0001
7.5 14.5 22.6 0.0001
7.3 28.9 25.8 0.92
8.0 8.4 3.2 0.99
, 16) 12 (6, 20) 16 (12, 20) 0.0001
8.6 31.3 16.7 0.0001
7.3 45.8 50.0
4.2 22.9 2.2
9.1 31.7 33.3 0.001
4.3 23.2 31.0 0.0001
; all body mass indexes (BMIs) are presented in kg/m2; and all blood pressure measurements are
vasive Imaging Research; HDL  high-density lipoprotein; LDL  low-density lipoprotein; TG NER
y Arte
101
(n 
62 (5
4
27 (2
215 (1
135 (1
50 (4
120 (8
95 (8
137 (1
83 (7
6
6
2
10 (4
4
3
1
2
1
mg/dlosts were similar across FRS subsets for all CAC subgroups.
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Costs of Coronary Calcium Screening September 29, 2009:1258–67umulative event-free survival. Overall death or MI-
ree survival was 98.7%. Figure 3 plots the cumulative
eath or MI-free survival by the CAC scores (p 
.0001) and FRS (p  0.0001). For CAC score, the
Figure 1 Downstream Stress Imaging and CCTA Rates After CA
(A) Cumulative rates of follow-up stress echocardiography or myocardial perfusion
artery calcium (CAC) subsets. The numbers in parentheses represent the number
1 to 10 revealed identical follow-up rates for coronary angiography. (B) Cumulative
4, and 6 in CAC subsets. *The number of patients available is the same as listedelative hazard increased 4.0- to 27.9-fold for those with tAC scores from 10 up to 1,000 (p  0.0001).
ndividuals with an intermediate-high FRS had an in-
reased hazard for death or MI (p  0.0001). The area
nder the curve, from the receiver-operating characteris-
-photon emission computed tomography at years 1, 2, 4, and 6 in coronary
ents available at each follow-up time point. *Subset analysis by CAC  0 versus
of follow-up coronary computed tomographic angiography (CCTA) at years 1, 2,
.C
single
of pati
rates
in (A)ic analysis, for the FRS was 0.71 (0.61 to 0.82, p 
0
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September 29, 2009:1258–67 Costs of Coronary Calcium Screening.001) with an added improvement to 0.79 (0.70 to 0.88,
 0.0001) for CAC scoring.
iscussion
he U.S. spends approximately $2 trillion each year on
ealth care, consuming more than 16% of our gross
omestic product, with imaging identified as influential
n promoting excess expenditures (15,16). Screening for
ung, breast, and colon cancer is a cornerstone of preven-
ive health and is considered cost effective because the
enefits of early detection offset procedural and induced
osts of care resulting in a reduced prevalence of more
dvanced, expensive downstream disease states (17). Dis-
ussions regarding CVD screening arise at a time when
rowth in imaging is double that of all other physician
ervices (15), at an estimated cost of $80 billion annually
18). Ongoing discussions of the advantages of expanding
overage for screening of preventable chronic diseases,
uch as CVD, can only now be advanced within the
ramework of a demonstrable societal benefit where
conomic evidence is clearly defined within the context of
dded value (i.e., quality) (19–21). Economic evaluations,
uch as that within EISNER, can then be used to inform
ealth care policy decisions (22–24).
The evidence of a clinical benefit of screening with CAC
s now substantial, with recent reports (3,25–28) on its
rognostic utility in ethnically-diverse populations of
omen and men. From a recent report, CAC improved
ortality risk reclassification in 25% to 45% of individuals
requency (Percentage) of Noninvasive Test Layering at 6 Monthsownstream Follow-Up Testing at 6 Months, 1 Y ar, and 4 Years oTable 2 Frequency (Perce t ge) of Noninv sive Test Lay ring aDownstream Follow-Up Testing at 6 Months, 1 Year, a
6 Months
CAC Subsets
No
Testing 1 Test
2 or More
Tests
N
Test
0–10 (n 773) 95.1 3.5 1.4 90
11–100 (n 287) 84.7 9.4 5.9 76
101–399 (n 187) 78.6 14.4 7.0 71
400–999 (n 83) 60.2 24.1 15.6 53
1,000 (n 31) 45.2 32.3 22.6 41
ll linear association chi-square; p  0.0001.
CAC  coronary artery calcium.
Frequency (Percentage) of Noninvasive Test LayTable 3 Frequency (Percentage) of Noninva
CAC Subsets
Noninvasive (Follo
ECG With Stres
0–10 (n 773) 11.3
11–100 (n 287) 19.5
101–399 (n 187) 8.1
400–999 (n 83) 28.9
1,000 (n 31) 51.6
All linear association chi-square; p  0.0001.
CCTA coronary computed tomographic angiography; ECG electrocardio
Table 2.ges 60 to 80 years when compared to the FRS. Despite
ffective risk stratification, concern over the “train” of CVD
ervices that may ensue after CAC scanning is frequently
oiced (29–31). The U.S. Preventive Services Task Force in
004 cautioned that harm potentiated from CVD screening
utweighed any benefit (1). They noted that excessive costs
nd harm associated with additional testing and possibly
abeling would exceed any derivable benefit from CVD
creening.
Our observations confirm that in an adult population
ith measureable CVD risk, ongoing preventive and diag-
ostic services frequently occur. Yet, annual CVD costs
ere low, at $25 to $35, for those with a CAC score 100,
nd notably, the subjects falling in this CAC score range
onstituted 78% of our screened population. By contrast,
ubstantial use of downstream testing and higher medical
osts were observed among the subjects with CAC scores
400, constituting 8.2% of the screened population. Of
articular interest in this regard, direct ICA was not
erformed immediately after CAC scanning with feeder
athways driven by the severity of ischemia and/or nonin-
asive coronary anatomy results before ICA referral. This
esult is consistent with a recent report noting that the
ddition of 1 CT scanner for cardiac applications resulted in
reduction in 15.4 (per 100 scanners) fewer ICAs (32). This
oncept of stepped testing has been reported as an effective
eans to reduce work-up costs by limiting additional
esting to only those with abnormal test results (7,8,33–36).
he observation that the rates of follow-up stress imaging
ow-Up in CAC Subsetsonths and
Years of Follow-Up in CAC Subsets
1 Yr 4 Yrs
1 Test
2 or More
Tests
No
Testing 1 Test
2 or More
Tests
5.8 3.6 72.5 16.4 11.3
15.0 8.7 56.3 20.4 23.3
17.1 11.8 49.5 20.7 29.9
24.1 22.9 34.9 31.3 33.8
25.8 32.3 16.1 19.4 64.5
in CAC Subsetsest Layering in CAC Subsets
Procedural Combinations
Exercise
ging)
Invasive (Follow-Up
Noninvasive Test Then ICA)
2.2
2.4
0.8
6.0
19.4andf Follt 6 M
nd 4
o
ing
.6
.3
.1
.0
.9eringsive T
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s Imagram; ICA invasive coronary angiography; other abbreviations as in
w
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Abbreviations as in Table 2.
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oncordant with clinical appropriate use criteria (37) and
ata demonstrating a threshold relationship between abso-
ute CAC scores and the likelihood of observing inducible
yocardial ischemia (7,8,34). Inducible myocardial isch-
mia is increasingly common among patients with CAC
cores 400, but the CAC threshold is influenced by
ertain CAD risk factors, such as diabetes and metabolic
yndrome (7) and the quality of patients’ chest pain symp-
oms (34).
Our data reveal that the differential in costs among our
tudy population were substantially wider with CAC scan-
Angiography After CAC
er of patients available is the same as listed in Figure 1A. The above curve is
es or stroke. Plotting of the results excluding previous hospitalization for acute
across the range of CAC scores. The call-out boxes indicate the odds ratio
e odds of coronary angiography were not significant for scores of 1 to 10
ations as in Figure 1.Figure 2 Downstream Invasive Angiography Rates and Probability of
(A) Cumulative rates of follow-up ICA at years 1, 2, 4, and 6 in CAC subsets. *The numb
calculated with the exclusion of 34 previous hospitalizations for acute coronary syndrom
coronary syndrome or stroke did not change the presented results. (B) Probability of ICA
(95% confidence intervals) for coronary angiography at 4 years for CAC scores 100. Th
(p  0.37) or 11 to 100 (p  0.11). ICA  invasive coronary angiography; other abbreviarly and Late Revascularizationtes (Percentage) by CAC SubsetsTable 4 Early and Late Reva cularizationRates (Percentage) by CAC Subsets
CAC Subsets <90 Days 1 Yr 4 Yrs
0–10 (n 773) 0.0 0.2 0.4
11–100 (n 287) 0.2 0.7 1.8
101–399 (n 187) 0.4 1.4 4.9
400–999 (n 83) 1.1 4.5 14.5
1,000 (n 31) 0.0 12.0 32.3
Wilcoxon chi-square p 0.36 p 0.0001ing compared to costs based on the FRS. When compared
w
t
c
i
g
p
s
i
p
p
a
c
m
t
s
p
p
r
c
a
f
C
p
a
E
* infarct
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September 29, 2009:1258–67 Costs of Coronary Calcium Screeningith noncardiac tests or blood markers, it remains plausible
hat CAC may also elicit a greater differential in procedural
osts and treatment costs when compared with other screen-
ng tests, but impact may vary by treatment. For example,
iven the therapeutic trials with high sensitivity C-reactive
rotein, one would anticipate a much larger increase in
tatin use than that elicited by CAC screening (38).
A Medicare Coverage Advisory Committee on medical
maging set one requirement for the addition of a
rocedure that it must reduce or minimize use of com-
arative modalities (39). To that end, CAC imaging
ppeared to minimize resource use among the large
ohort of subjects for those with low-risk scores, with the
Figure 3 Event-Free Survival by CAC and FRS
Cumulative event-free survival in CAC and Framingham Risk Score (FRS) subsets.
(HRs) (95% confidence intervals [CIs]). *FRS-adjusted HR data. Abbreviations as in
stimated Annual Cardiovascular Procedural and Overall* Costs inTable 5 Estimated Annual Cardiovascular Procedural and Overa
Mean and Quart
CAC Subsets
% of
Subjects
Procedural
Costs†
50th (25th, 75th)
Percentile
0–10 (n 773) 56.7% $177 $25 ($0, $290)
11–100 (n 287) 21.0% $444 $35 ($0, $632)
101–399 (n 187) 13.7% $874 $144 ($0, $870)
400–999 (n 83) 6.0% $1,888 $533 ($27, $1,391)
1,000 (n 31) 2.2% $4,457 $1,437 ($716, $36,72
Wilcoxon chi-square p 0.0001
Overall costs include drug therapy, hospitalizations (for stroke, chest pain, and acute myocardial
Abbreviations as in Table 2.ajority of “high-end” resource consumption limited to
he much smaller cohort of subjects with high-risk CAC
cores. Similarly, greater drug therapy utilization in
atients with high-risk CAC scores was previously re-
orted (40). Previous reports (41) have noted a close
elationship (r2  0.78) between ICA and percutaneous
oronary intervention. In the pre-ICA setting, we noted
similar relationship between ischemia testing and ICA
or patients with high-risk CAC.
On the basis of the current results, previous concern as to
AC scanning leading to frequent ICA in asymptomatic
atients was not realized in our study (42). Rather, at 1 year
fter testing, ICA was performed 1% of subjects with
d in each survival curve is a table of the hazard ratios
e 1.
Subsetsosts in CAC Subsets
nual Cost (Including Index Testing Cost)
% of
Costs
Overall
Costs*†
50th (25th, 75th)
Percentile
% of
Overall Costs
18.9% $675 $353 ($45, $1,158) 35.0%
17.6% $1,132 $673 ($182, $1,379) 21.8%
22.6% $1,361 $610 ($179, $1,332) 17.1%
21.7% $2,357 $1,167 ($493, $2,152) 13.1%
19.2% $6,177 $1,365 ($812, $9,482) 12.9%
p 0.0001
ion), and smoking costs; †mean.Include
FigurCACll* C
ile An
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AC scores 1,000.
tudy limitations. Of importance, the generalizability of
he current finding is limited to registries with similar
nrollment strategies and admixture of risk factors. From
he current study, 1.4% of enrollees were lost in follow-up.
ndividuals lost during follow-up were similar to those
ncluded herein. Follow-up test interpretations were self-
eported or inconsistently available. Test interpretations
ould help to further unfold the effectiveness of a CVD
creening program. To preserve subject anonymity as re-
uired by our Institutional Review Board, test results were
ot sent directly to the subjects’ physicians, but subjects
ere encouraged to share their screening results with private
hysicians, especially if a new or high-risk factor, such as a
alcium score 400, was detected. We did not include
ndirect costs or patient preferences that may further aid in
efining the societal benefit of CVD screening (43). Hos-
ital and outpatient bills were not available and could have
mproved the precision of our cost estimates, although we
sed a systematic approach by applying uniform costing
hroughout this analysis. Given the diversity in reimburse-
ent across a given private and public payers, we chose to
pply Medicare reimbursement rates as an attempt to
stimate costs. As a result, some of our estimated costs may
ot be applicable to non-Medicare patient populations.
perational within follow-up interviews is the potential for
ecall bias to result in an under- or over-estimation of
ollow-up resource use data. Moreover, the aim of the
urrent report was to examine induced procedure use, and
e did not include patterns of outpatient visits to generalists
r cardiologists that may be important and contributory to
his analysis.
onclusions
he costs of CVD on the health care system are substantial
nd, similar to other chronic conditions, appear greatest in
he initial diagnosis and final phases of life (23,44–46).
ccordingly, concern for adding costs by approving third-
arty coverage for CAC scanning has been understandable.
n the other hand, the frequent occurrence of sudden death
s the first manifestation of CAD (47) represents an
nsolved health problem requiring better means for screen-
ng for CAD. Ideally, an acceptable cost-effective screening
est for CAD would reliably identify a high risk subgroup
or aggressive follow-up that would, however, constitute
nly a small fraction of the screened population. The results
f this study are consistent in this regard. CAC scanning
dentified a high risk subgroup of subjects with CAC scores
400, who have been shown by prior epidemiological study
o be at increased risk for future cardiac events and are
nown to concurrently have an increased risk for inducible
yocardial ischemia (7,8,34). This high-risk subgroup had
ubstantially increased medical costs and downstream test-
ng, but importantly, this group only constituted 8.2% of ourtudy population. Those at very high risk, by virtue of CAC
cores 1,000 had a marked increase in medical costs, but
nly constituted 2.2% of the study population. Conversely,
ownstream medical costs were very low among the large
ool of subjects with low CAC scores in our study
CAC scanning was initially introduced into medical
ractice solely as a screening test for CAD, but the obser-
ation that this test also helps predict the likelihood of
nducible myocardial ischemia means that the test may not
nly serve as a means for detecting latent CAD but also, as
potential gatekeeper for determining the need for subse-
uent medical testing, and invasive procedures that may
ollow, among subjects with suspected CAD. The findings
f our study suggest that CAC may play an important role
n fostering more efficient, selective testing patterns in
symptomatic individuals at risk for CVD.
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